Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab-based chemotherapy comparison in relapsed or metastatic head and neck squamous cell carcinoma
2010-022924-57Phase 2Completed
- Sponsor
- Radiumhemmet
- Start
- Jul 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Radiumhemmet. Primary endpoint: Progression-free survival rate. Started Jul 2011; status: completed.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2010-022924-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022924-57.